DefaultJul 20, 2026, 04:47 PM
Sangamo Therapeutics Sets Asset Sale Deadlines Amid Bankruptcy
AI Summary
Sangamo Therapeutics, Inc. is proceeding with its Chapter 11 bankruptcy, with the court approving bidding procedures for the sale of its assets. Key deadlines include an August 4, 2026 bid deadline, an August 10, 2026 auction date, and an August 20, 2026 sale hearing. Additionally, Nasdaq has denied the company's request to continue its listing, and Sangamo does not intend to appeal this decision, leading to its common stock trading on the OTCID Basic Market.
Key Highlights
- Company filed for Chapter 11 bankruptcy on June 23, 2026, in Delaware.
- Court approved bidding procedures for asset sale on July 14, 2026.
- Bid deadline for interested parties is August 4, 2026, at 5:00 p.m. ET.
- Asset auction, if multiple bids, is scheduled for August 10, 2026, at 10:00 a.m. ET.
- Sale Hearing to approve successful bids is set for August 20, 2026, at 10:00 a.m. ET.
- Nasdaq denied continued listing; company does not intend to appeal the decision.
- Common stock currently trades on the OTCID Basic Market under the symbol "SGMOQ".
Price Impact
More from SGMO